Compare MG & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MG | KMDA |
|---|---|---|
| Founded | 1978 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 424.6M | 458.6M |
| IPO Year | 2009 | N/A |
| Metric | MG | KMDA |
|---|---|---|
| Price | $14.19 | $8.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 185.1K | 82.2K |
| Earning Date | 03-04-2026 | 03-04-2026 |
| Dividend Yield | N/A | ★ 2.31% |
| EPS Growth | ★ 60.33 | 30.41 |
| EPS | ★ 0.57 | 0.35 |
| Revenue | ★ $715,300,000.00 | $174,787,000.00 |
| Revenue This Year | $1.51 | $14.79 |
| Revenue Next Year | $3.30 | $11.38 |
| P/E Ratio | ★ $24.37 | $24.63 |
| Revenue Growth | N/A | ★ 10.36 |
| 52 Week Low | $7.06 | $5.54 |
| 52 Week High | $14.70 | $9.16 |
| Indicator | MG | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 60.87 | 61.02 |
| Support Level | $13.72 | $7.85 |
| Resistance Level | $14.45 | $8.88 |
| Average True Range (ATR) | 0.41 | 0.22 |
| MACD | -0.07 | 0.05 |
| Stochastic Oscillator | 64.74 | 59.02 |
MISTRAS Group Inc provides asset protection solutions and systems. The company evaluates the structural integrity and reliability of critical energy, industrial, and public infrastructure. The company's three operating segments are North America, International and Products and Systems, of which key revenue is derived from the North America segment. Services segment provides asset protection solutions predominantly in North America, with the large amount of concentration in the United States, followed by Canada, consisting of non-destructive testing, and inspection. The asset protection solutions include field inspections, consulting, maintenance, data management, access, monitoring and laboratory quality assurance.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.